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Background: Propolis is a multicomponent active, complex resinous substance collected by
honeybees (Apismellifera) fromavariety of plant sources. This studywasdesigned to improve
the antimicrobial efﬁcacy of propolis by engineering a niosomal-based system for topical
application.
Methods: Propolis was extracted in ethanol and screened for total polyphenol content.
Propolis-loaded niosomes (PLNs) were prepared with varying concentrations of Span 60
and cholesterol. The PLNs were evaluated for physicochemical parameters, namely, vesicle
size, entrapment efﬁciency, zeta potential, surface topography and shape, and stability, fol-
lowed by screening for in vitro antimicrobial activity. The PLNs were formulated into propolis
niosomal gel (PNG) using Carbopol P934 base and subjected to ex vivo skin deposition study.
Results:The ethanolic extract of propolis hadhigh polyphenolic content (270±9.2mgGAE/g).
The prepared PLNs showed vesicle size between 294nmand 427nm, and the percent entrap-
ment in the range of 50.62–71.29% with a signiﬁcant enhancement in antimicrobial activity
against Staphylococcus aureus and Candida albicans. Enhanced antimicrobial activity of PLNs
was attributed to the ability of niosomes to directly interact with the bacterial cell envelop
thereby facilitating the diffusion of propolis constituents across the cell wall. The formu-
lated PNG exhibited a twofold better skin deposition due to improved retention of niosomes
in the skin.Conclusion: The ﬁndings indicate that the engineering of a niosomal-based system for propo-
lis enhanced its antimicrobial potential through topical application.
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. Introduction
ropolis is a complex resinous substance (sometimes referred
o as bee glue) collected by honeybees, especially Apis mel-
ifera, from a variety of plant sources including cracks in
ark and leaf buds. Propolis is a strong adhesive material.
s such, it is used by bees in the construction, maintenance,
nd protection of their hives.1,2 It has a complex chemi-
al composition and is known to be rich in polyphenols,
avonoids, waxes, resins, balsams, amino acids, oils, etc.3
ropolis is reported to have a wide array of pharmacologi-
al activities such as antioxidant, anticancer, antimicrobial,
ntiviral, immunomodulatory, wound healing, and antileish-
anial properties.4–12 Despite its broad therapeutic potential,
ts complex resinous nature, low solubility, sticky consistency,
nd physical instability present a major hurdle with regard to
ts processing and formulation development.6,10,13
Several studies have reported on the broad-
pectrum antimicrobial properties of propolis and its
onstituents.6–8,11,13–17 Propolis has shown strong bactericidal
ctivity against several Gram-positive and Gram-negative
acteria. Propolis and some of its cinnamic and ﬂavonoid
omponents were found to uncouple the energy-transducing
ytoplasmic membrane and to inhibit bacterial motility.14
everal studies have explored the antifungal properties of
ropolis.4,15,17 Although the mechanism of action for its
ntimicrobial effect is not yet clearly understood, some
tudies suggest that propolis constituents interfere with the
ivision of bacterial cells through the formation of pseu-
omulticellular forms, cytoplasm disorganization, protein
ynthesis inhibition, and cell lysis.18 The antimicrobial effect
f propolis is correlated with its complex composition com-
rising ﬂavonoids; ferulic acid; caffeic acid derivatives such
s caffeic acid phenyl ester (CAPE); hydroquinones; terpenic
cids such as isopimaric, abietic and dehydroabietic acid;
alangin; pinostrobin; and pinocembrin content.4,6
The antimicrobial efﬁcacy of propolis can be better used for
reating several bacterial or fungal infections by fabricating a
elivery system, which will prolong its diffusion and improve
etention of its constituents in the skin through topical appli-
ation.
Vesicular delivery systems such as niosomes are reported
o improve the dermal or topical delivery of various poorly sol-
ble actives by enhancing solubility and permeability along
ith retention into the skin.19–21 Niosomes enhance the res-
dence time of drugs in the stratum corneum and epidermis
hile reducing the systemic absorption of the drug.21–23 These
onionic surfactant vesicles modify stratum corneum prop-
rties, improve the penetration of trapped substances across
he skin, and act by reducing transepidermal water loss,
hereby increasing smoothness by replenishing skin lipids,
nd thus, enhancing the potential of the entrapped drug
dministered topically.24,25 Considering the evident charac-
eristics of niosomes, it was hypothesized that developing a
iosomal-based formulation for propolis would enhance its
ntimicrobial efﬁcacy through topical application. Our group
as previously traced a liposomal delivery system for propo-
is as a means of enhancing its hepatoprotective activity.26
his work was designed with the objective of developing a95
niosomal-based delivery system for propolis to improve its
antimicrobial potential through topical application.
2. Methods
Propolis was generously supplied by Nature Laboratory Ltd.
(Whitby, North Yorkshire, UK). Span 60, cholesterol, sodium
hydroxide, and potassium dihydrogen phosphate were pro-
cured from Sigma-Aldrich Ltd. (Mumbai, India). Stearic acid
was purchased from HiMedia Laboratories (Mumbai, India).
Ethanol, acetonitrile, and methanol were purchased from
Merck Ltd. (Mumbai, India). All the chemicals and solvent used
in this study were of analytical grade.
2.1. Determination of total polyphenol content of
propolis
The crude propolis (2 g) was extracted with absolute ethanol
(40mL) for 24hours at room temperature by maceration
using a mechanical shaker at 200 rpm followed by centrifuga-
tion. The supernatant obtained was ﬁltered and concentrated
under reduced pressure to obtain ethanolic extract of propo-
lis (PEE).27 The total polyphenol content in the extract was
determined by the Folin–Ciocalteu method.9,28 In brief, the
PEE (1mL) was mixed with Folin–Ciocalteu’s phenol reagent
(1mL). To thismixture, an aqueous solution of sodium carbon-
ate (7%, 5mL) was added and diluted to 25mL with distilled
water. Absorbance was measured at 760nm using the JASCO
V-630 UV–visible spectrometer, (Tokyo, Japan) after 90minutes
of incubation of the mixture at room temperature. The total
polyphenol contents were expressed in terms of milligram
gallic acid equivalents (GAE)/g.
2.2. Preparation of propolis-loaded niosomes
The ethanol injection method was optimized for preparing
blank niosomes (empty vesicles) and propolis-loaded nio-
somes (PLNs, i.e., loaded vesicles). Different batches (J1, J2, J3,
J4, J5, and J6) were prepared by varying molar ratios of Span 60
to cholesterol (1:0, 1:1, 1:1.5, 1:2, 1.5:1, and 2:1), respectively. In
accordance with the molar ratios, measured amounts of Span
60, cholesterol, PEE (20mg), and stearic acid (7mg) were dis-
solved in 4mL of ethanol. The mixture was injected using a
syringe into 10mL of distilled water maintained at 60–65 ◦C.
The mixture was continuously stirred using a magnetic stirrer
for 60minutes to ensure complete evaporation of the solvent.
The prepared niosomes were refrigerated for complete sealing
of the surfactant bilayer. The niosomes were then character-
ized.
2.3. Characterization of niosomes
2.3.1. Vesicle-size analysis and size distribution
Mean vesicle size and size distribution of PLNs were deter-
mined using a particle-size analyzer (Malvern 2000SM;
Malvern Instruments Ltd., Malvern, United Kingdom). The
laser obscuration was maintained at 1–2.5% with the angle of
detection at 90◦. The experiment was performed in triplicate.
96
2.3.2. Entrapment efﬁciency
The entrapment efﬁciency (EE) of the prepared PLN was deter-
mined in terms of total polyphenol content of the PEE using
the centrifugation method.21 The PLN dispersion in distilled
water was centrifuged at 20,000 rpm at 4 ◦C for 1 hour. The
supernatant was separated from the pellet and the amount of
unentrapped drug in terms of total polyphenol content was
determined by the Folin–Ciocalteu method.9,28 The EE of the
prepared PLN was calculated using the following equation:
EE = [(Ct − Cf )/Ct] × 100
where Ct is total polyphenol content of propolis and Cf is total
polyphenol content of propolis in the supernatant.
2.3.3. Zeta potential determination
To assess the stability of the prepared niosomes, 1-mL aliquots
of the prepared niosomal dispersions were diluted 100-fold
with distilled water and assessed for zeta potential ()using
Zetasizer 300HsA (Malvern Instruments Ltd.).
2.3.4. Transmission electron microscopy
The surface topography and shape of the PLNs were observed
by transmission electron microscopy. A drop of niosomal dis-
persion was placed on the copper mesh grid. Upon adsorption
of sample after 15minutes, the staining dye potassium phos-
photungstate was dripped onto the ﬁlm. The grid was dried
under an infrared lamp for approximately 30minutes and
photographs were taken using a Zeiss EM 109 transmission
electron microscope (Ostalbkreis, Germany).
2.3.5. Stability study
Optimized PLN dispersion (Batch J6) was subjected to a
stability study at 25±2 ◦C/60% relative humidity (RH) and
45±2 ◦C/75% RH for 90 days. The physical stability was
assessed in terms of vesicle size as described earlier.
2.4. Antimicrobial activity
The minimum inhibitory concentrations (MICs) for PLN and
PEE were determined by serial tube dilution method7,8 in the
concentration range of 50–500g/mL. The antimicrobial activ-
ities of PLN and ethanolic solution of propolis were compared
by determining the zone of inhibition using the agar gel diffu-
sion method14 against Staphylococcus aureus (ATCC 6538P) and
Candida albicans (ATCC18804; both strainswere supplied by the
National Collection of IndustrialMicroorganisms, Pune, India).
The bacterial culture was grown in a nutrient broth at 37 ◦C
for 24hours and the fungal culture was grown in Sabouraud
dextrose broth, followed by incubation at 25 ◦C for 48hours.
Approximately 100L of cultures were seeded individually in
25-mL molten nutrient agar, mixed and poured into sterile
Petri plates, and allowed to solidify. Different concentrations
of PLN and PEE were added into the bore well (diameter: 8mm)
in the agar plates followed by incubation at 37 ◦C for 24hours.
The zone of inhibition was measured and recorded.2.5. Preparation of propolis niosomal gel
The optimized PLN (Batch J6) was formulated into a gel for top-
ical application consisting of 1% (w/w) Carbopol P934 gel base.Integr Med Res ( 2 0 1 5 ) 94–101
The Carbopol was added gradually into the PLN (J6) disper-
sion with continuous stirring. The mixture was kept overnight
to allow for swelling of the gel, which conﬁrms complete
hydration of polymer chains. The formed gel was analyzed for
drug content and subjected to ex vivo skin deposition study.
Similarly, a control gel comprising an equivalent amount of
PEE in Carbopol was formulated. Drug content in terms of
CAPE was determined for both by extracting 1 g of gel in
ethanol, dilutedwith themobile phase (acetonitrile:methanol)
by high-performance liquid chromatography (HPLC) using a
UV detector at 325nm.29
2.6. Ex vivo skin deposition study
The ex vivo deposition study was carried out on Wistar rat skin
according to the study protocol approved by the Institutional
Animal Ethics Committee constituted under the Committee
for the Purpose of Control and Supervision on Experimental
Animals (India). A vertical Franz diffusion cell with a reser-
voir capacity of 22mL was used for the study. The excised
and defatted rat skin was mounted between the donor and
receptor compartments of the vertical Franzdiffusion cellwith
an effective permeation area of 1.5 cm2. The 2-mL receptor
solution of phosphate buffer (pH 7.4) was continuously stirred
using a magnetic bar and maintained at 37 ◦C for 24hours.
Individually, 1 g of propolis niosomal gel (PNG) and the control
gel sample were applied over the skin into the donor com-
partment. After 24hours, the skin was cleaned using a cotton
cloth, ﬁnely divided, and subjected to homogenization with
acetonitrile:methanol (50:50) and sonicated for 30minutes.
The mixture was centrifuged to sediment the cells and tis-
sues of the skin. The supernatantwas diluted using themobile
phase acetonitrile:methanol (50:50) and subjected to drug
content determination in terms of CAPE usingHPLC. The anal-
yses were performed on a JASCO HPLC system (Tokyo, Japan)
with a Thermo Scientiﬁc Hypersil GOLD C18 reversed-phase
chromatography column (250mm × 4.0mm, 5m) using a UV-
visible detector. Elution was carried out with a ﬂow rate of
1mL/min at ambient temperature. Detection was performed
at 325nm.
3. Results
3.1. Total polyphenol content of propolis
Propolis is commercialized in various regions of the world
and is recognized as a vital source of constituents such as
phenolics, which are responsible for several pharmacologi-
cal effects.30 The PEE showed a high polyphenol content of
270±9.2mg GAE/g. Evaluating the polyphenol content is con-
sidered a means to determine the entrapment efﬁcacy of
developed PLN.
3.2. Vesicle size and EETable 1 presents the results of vesicle size and % EE for the pre-
pared niosomes. A clear increase in vesicle size was observed
for all batches of PLN compared with that of empty vesi-
cles (Fig. 1). The results for vesicle-size analysis demonstrated
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Table 1 – Effect of variables on vesicle size and entrapment efﬁciency
Batches Span
60:cholesterol
Size of empty
vesicles d(0.9) nm
Size of loaded
vesicles d(0.9) nm
% Entrapment efﬁciency
J1 1:0 182±3.08 294±5.53 52.85±1.95
J2 1:1 173±5.53 327±3.53 * 55.85±2.49
J3 1:1.5 189±3.53 307±2.52 50.62±1.71 †
J4 1:2 195±2.08 317±3.15 50.96±1.32
J5 1.5:1 211±4.53 334±4.52 † 67.31±4.89 *
J6 2:1 217±3.00 427±5.52 * 71.29±5.32 *
Values are expressed as mean ± standard deviation (n=3) followed by one-way analysis of variance with Tukey’s multiple comparison test.
∗ p<0.001.
† p<0.05.
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fFig. 1 – Vesicle-size analysis and entrapmen
signiﬁcant increase initially (p<0.001) in the size of PLN
atch J2 compared with that of Batch J1. A signiﬁcant decline
p<0.001) in the size of PLN Batch J3 followed by a gradual
ncrease in the size for Batches J4, J5, and J6 was observed. The
esicle size for PLN Batches J5 and J6 showed signiﬁcant aug-
entation (p<0.05 and p<0.001, respectively) compared with
hat of Batch J2. The results of EE for PLN showed a signiﬁcant
ecline (p<0.05) for Batch J3 compared with that of Batch J2.
signiﬁcant improvement (p<0.001) in EE of PLN Batches J5
nd J6 was observed compared with that of Batch J2..3. Zeta potential determination
he zeta potential () for the prepared PLN was found to range
rom –33.2mV to –38.8mV.ciency of propolis-loaded noisome batches.
3.4. Transmission electron microscopy
The transmission electron microscopy image for PLN (Fig. 2)
depicts a spherical shape and smooth surface. The size range
of PLN was found to be between 294nm and 427nm.
3.5. Stability study
The stability study for the optimized PLN (Batch J6) did not
show a signiﬁcant change in mean vesicle size over 90 days
of study (data not shown). In addition, no signs of aggregation
or sedimentation were observed, indicating the formation of
stable niosomal dispersion.
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Fig. 2 – Transmission electron microscopy image of
propolis-loaded niosomes.
signiﬁcant increase (p<0.001) in entrapment of propolis con-
stituents as observed in Table 1. The increase in the EE of3.6. Antimicrobial activity
The antimicrobial activities of PLN (Batch J6) and the ethanolic
solution of propolis were compared. The MIC of PLN against
S. aureus and C. albicans was found to be lower in compari-
son with that of the ethanolic solution of propolis (Table 2).
PLN signiﬁcantly increased the zone of inhibition (p<0.05;
Table 2) against both S. aureus and C. albicans as displayed in
Fig. 3.
3.7. Ex vivo skin deposition study
For ease of application and for improving their retention in
the skin, the PLNs were formulated into gel using Carbopol
P934 gel base. Because polyphenols are a group of com-
pounds having variation in chemical structures with a wide
range of polarity, they possess different coefﬁcients of per-
meability. Therefore, CAPE, one of the major active phenolic
constituents of propolis, was analyzed for ex vivo skin depo-
sition study. The mean drug content in terms of CAPE from
PNG and the control gel was found to be 55.92±1.43g/g
and 54.88±3.09g/g, respectively. Estimation of mean drug
deposition of PNG and the control gel in the excised rat
skin was found to be 9.3±2.0g/cm2 and 4.7±1.6g/cm2,
respectively.
Table 2 – Antimicrobial effect of PLN and ethanolic solution of p
Formulation Antibacterial activity aga
Staphylococcus aureus
MIC (g/mL) Zone of inhib
Ethanolic solution of propolis 500 15.3±1.5
PLNs 300 25±3.00
Values are expressed as mean ± standard deviation (n=3) followed by one
∗ p<0.05.
MIC, minimum inhibitory concentration; PLN, propolis-loaded noisome.Integr Med Res ( 2 0 1 5 ) 94–101
4. Discussion
In this work, attempts have been made to develop niosomal-
based delivery for propolis to improve its therapeutic efﬁcacy
through topical application. The ability of niosomes to
improve dermal delivery of actives by enhancing their
retention in the skin was thought to be useful for better
achievement of therapeutic activity in terms of antimicrobial
effect through topical application. Among various methods
initially tried in this regard, the ethanol injection method pro-
duced PLN with desired physicochemical characteristics. At
the outset, the optimal molar concentrations of Span 60 and
cholesterol were determined to obtain stable niosomes free of
aggregation, fusion, and sedimentation.
4.1. Inﬂuence of variables on vesicle size and EE
The amount of Span 60 and cholesterol showed profound
inﬂuence over vesicle size and EE of niosomes. The observed
signiﬁcant decline (p<0.001) in the size of PLN Batch J3 com-
pared with that of Batch J2 can be attributed to the effect
of cholesterol. Previous studies have shown that vesicle size
reduces upon addition of cholesterol due to reduction in the
curvature of vesicles because of interactive forces between
Span 60 and cholesterol.31 However, further augmentation
in the vesicle size of Batch J4 with an increased amount
of cholesterol might be attributed to the increase in bilayer
thickness on account of the probable association of the 3-OH
group of cholesterol with propolis constituents. Similar effect
was observed during fabrication of ciclopirox niosomes using
cholesterol.32 Furthermore, the observed increase in PLN size
for Batches J4, J5, and J6 can be attributed to the effect of Span
60. The diameter of niosomal vesicles is dependent on the
length of alkyl chain of surfactants. Surfactants with longer
alkyl chains produce larger vesicles.33 The long C18 stearyl
chain of Span 60 contributes to larger vesicle size.31,33 Further,
the incorporation of propolis and its distribution within the
bilayer might have contributed to the increase in the overall
vesicle size of PLN compared with that of the empty vesi-
cles. The EE of niosomes was found to be directly proportional
to the concentration of Span 60, that is, as the concentra-
tion of surfactant increased linearly (J4, J5, J6), there was aPLN was attributed to the higher amount of matrix avail-
able for propolis to be distributed within the bilayer with
ropolis
inst Antifungal activity against Candida
albicans
ition (mm) MIC (g/mL) Zone of inhibition (mm)
3 400 10.7±1.15
* 300 20±2.00 *
-way analysis of variance with Tukey’s multiple comparison test.
J. Patel et al/Propolis antimicrobial efﬁcacy 99
Fig. 3 – Antibacterial activity of: (A) propolis-loaded noisome (PLN); and (B) ethanolic solution of propolis. Antifungal activity
of: (C) PLN and (D) ethanolic solution of propolis.
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vncreasing concentrations of Span 60. In addition, increasing
he molar concentration of cholesterol from 0 to 1 (J1, J2, J5,
nd J6; Table 1) improves the EE of niosomes owing to the
embrane-stabilizing effect of cholesterol.31 The cholesterol
ffectively gets distributed between the bilayer and occupies
oid space, thereby decreasing the ﬂuidity of the membrane
nd making it rigid.21,31 Incorporation of cholesterol increases
he bilayer hydrophobicity and stability of niosomes,34 reduc-
ng the permeability.35 This might lead to efﬁcient trapping of
ropolis into the bilayers forming vesicles. It also decreased
eakage from niosomes, thereby increasing the EE. Further
ncrease in the cholesterol content (J3 and J4) declined the EE
s it competes with propolis constituents for packing space
ithin the bilayer (Fig. 1).31
Zeta potential reﬂects the charge present on the surface
f the vesicle responsible for intervesicular repulsion, which
revents vesicle aggregation. The observed values for  for the
repared PLN indicate the formation of stable niosomes with-
ut intravesicular aggregation. The ethanol injection method
s postulated to form small unilamellar vesicles.32 The trans-
ission electron microscopy analysis conﬁrmed the spherical
hape and size of PLN. No signiﬁcant change in the mean
esicle size and the absence of any signs of aggregation orsedimentation indicate the formation of stable niosomal dis-
persion.
The observed increase in the zone of inhibition with PLN
(Table 2) against bacterial and fungal strains may be attributed
to the ability of the vesicular delivery system to directly inter-
act with the bacterial cell envelope, and thus, facilitating
diffusion across the cell wall.29,36 Vesicles such as liposomes
have been reported to enhance the penetration of antibiotics
by fusion with the bacterial cell.36 Furthermore, the niosomes
protect an encapsulated drug from the action of bacterial
enzymes as well as facilitate its diffusion across the bacterial
cell wall.37 The MIC and zone of inhibition for PLN conﬁrm the
enhanced antimicrobial effect of propolis entrapped in nio-
somes comparedwith that of an ethanolic solution of propolis,
thereby conﬁrming its improved antimicrobial potential.
Drug deposition is a signiﬁcant parameter that determines
theperformanceof the topically delivered system.Theefﬁcacy
of a topical delivery system is affected by its retention within
the skin. The results of drug deposition indicate that PNG
showed approximately twofold better skin deposition com-
pared with that of the control gel (Fig. 4). The increase in skin
deposition is directly attributed to the niosomal vesicles com-
prising nonionic surfactant. Niosomes are adsorbed on the
100 Integr Med Res ( 2 0 1 5 ) 94–101
from
rFig. 4 – Ex vivo skin deposition of propolis
outermost layer of the stratum corneum by forming stacks
of bilayer on the top of the stratum corneum,22,23,34,38 thereby
enhancing the skin deposition shown by PNG as compared
with the control gel.
5. Conclusion
This study demonstrates the successful formulation of a
vesicular delivery system in the form of niosomes for mul-
ticomponent active propolis to improve its antimicrobial
potential through topical application. The PLN possessed
desired characteristics in terms of vesicle size, EE, and zeta
potential. The amount of surfactant and cholesterol used
exerts a profound effect on the vesicle size and EE. The formu-
lated PNG demonstrates enhanced skin deposition in terms of
CAPE, thereby proving the applicability of a niosomal delivery
system to several multicomponent actives such as propolis to
improve their therapeutic efﬁcacy.
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